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Abstract
Phospholamban (PLB) is a pentameric protein that plays an important role in regulating cardiac contractility via a reversible
inhibitory association with the sarcoplasmic reticulum Ca2+ATPase (SERCA), the enzyme responsible for maintaining correct
calcium homeostasis. Here we study the functional and biophysical characteristics of a PLB mutant associated with human
dilated cardiomyopathy (DCM), with a deletion of arginine at position 14 (PLBR14D). In agreement with recent findings, we
find that PLBR14D has a reduced inhibitory effect on SERCA compared to wild type PLB (PLBWT) when reconstituted into
lipid membranes. The mutation also leads to a large reduction in the protein kinase A-catalysed phosphorylation of Ser-16 in
the cytoplasmic domain of PLBR14D. Measurements on SERCA co-reconstituted with an equimolar mixture of PLBWT and
PLBR14D (representing the lethal heterozygous state associated with DCM) indicates that the loss-of-function mutation has
a dominant effect on PLBWT functionality and phosphorylation capacity, suggesting that mixed PLBWT/PLBR14D pentamers
are formed that have characteristics typical of the mutant protein. Structural and biophysical analysis of PLBR14D indicates
that the mutation perturbs slightly the helical structure of the PLB cytoplasmic domain and reduces its affinity for the
phospholipid bilayer surface, thereby altering the orientation of the cytoplasmic domain relative to the wild-type protein.
These results indicate that the structure and function consequences of the R14 deletion have profound effects on the
regulation of SERCA which may contribute to the aetiology of DCM.
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Introduction
Cardiac contractility is determined by tight regulation of
calcium transients within cardiac myocytes, with the force of
contraction and rates of relaxation in part determined by the
calcium-pumping action of the sarcoplasmic reticulum Ca2+-
ATPase (SERCA2a). Phospholamban (PLB) is a 52 amino acid
single-pass transmembrane protein located in the sarcoplasmic
reticulum (SR) membrane, where it exists in dynamic equilibrium
between monomeric and pentameric forms [1,2]. PLB acts as a
critical regulator of SERCA2a, the action of which involves a
finely-tuned balance between kinases and phosphatases that are
essential for the regulation and control of PLB activity and in turn,
regulation of SERCA [2–5].
Under conditions of low [Ca2+], the monomeric form of PLB
interacts with SERCA reducing the calcium affinity of the enzyme
and reducing the rate of calcium uptake by the sarcoplasmic
reticulum (SR) [4]. Inhibition is relieved by an increase in [Ca2+]
or by protein kinase A catalysed phosphorylation of PLB at Ser16
and/or Thr17 in response to b-adrenergic stimulation [6].
Phosphorylation of PLB is believed to alter the contacts between
SERCA and PLB, relieving inhibition but not necessarily leading
to dissociation of the two proteins [7]. The monomeric form of
PLB appears to interact with SERCA [8], but pentamers may also
be involved in the fine control of SERCA regulation by acting as a
reservoir controlling the precise concentration of monomer
available to interact with the enzyme [9,10]. PLB comprises four
structural domains: a helical cytoplasmic domain Ia (residues 1–
16), a loop region (residues 17–22), a helical domain Ib at the
membrane cytoplasmic interface (residues 23–30) and a helical
transmembrane domain II (residues 31–52) [11–13]. The trans-
membrane domain lowers the affinity of SERCA for calcium at
non-saturating concentrations and the cytoplasmic domain has a
small effect on the maximal activity of SERCA, and contains the
phosphorylation sites. The main structural state populated by PLB
in cell membranes is believed to be a so-called T state, in which the
cytoplasmic helices are oriented approximately perpendicular to
the transmembrane helix and making contact with the surface of
the lipid bilayer [14]. Phosphorylation increases the population of
a dynamic, structurally disordered ‘‘R state’’ which detaches from
the membrane [14,15].
Mutations in human PLB are known to cause familial
cardiomyopathies; in particular there have been identified two
mutations that result in dilated cardiomyopathy (DCM), the
variants PLB R9C (a substitution of residue Arg9 for Cys), and
PLB R14D (a deletion of residue Arg14) [16–18]. The R9C
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mutation is a dominant loss-of-function (LOF) mutation, which
generates a highly pentameric form of PLB as a result of the extra
cysteine residue and, in consequence, less of the monomeric form
is available to interact with SERCA [19,20]. Monomeric R9C,
which exerts an inhibitory effect on SERCA, is fully capable of
being phosphorylated with subsequent relief of inhibition [19], but
sequestration into the pentamer renders R9C unavailable for
phosphorylation by cAMP-dependent protein kinase A (PKA),
which cannot gain access to Ser16. The R14D mutation alters the
signal sequence for correct location of PLB to the SR [21], and
also disrupts the upstream consensus sequence for PKA phos-
phorylation at S16. Studies in mice reveal that in the absence of
wild-type PLB (the homozygous state), R14D results in incorrect
localisation to the plasma membrane allowing PLBR14D to
interact with and activate Na+ K+-ATPase (NKA) [22]. This
activation may be direct or indirect by interfering with the
naturally inhibitory interaction between NKA and phospholem-
man (PLM). In the presence of equimolar PLBWT (the
heterozygous state associated with DCM), correct localisation of
PLBR14D to the SR occurs, allowing it to interact with and inhibit
SERCA. Haghighi and co-workers showed that heterozygous PLB
has a super-inhibitory effect on SERCA when co-expressed in
HEK-293 cells, which is only partially reversed after phosphor-
ylation of PLB [17]. Ceholski and co-workers subsequently
reported that deletion of Arg14 disrupts the PKA recognition
motif in the PLB cytoplasmic domain, which abolishes PLB
phosphorylation and leads to constitutive inhibition of SERCA
[23].
Here we study the structure-function relationship of PLB R14D
reconstituted into phospholipid membranes with SERCA in the
presence and absence of PLBWT. We show that the mutant in
these membranes has a slightly reduced inhibitory effect in
comparison to wild-type PLB and is resistant to phosphorylation
by PKA. Structural analysis using solid-state nuclear magnetic
resonance (ssNMR) and circular dichroism spectroscopy indicate
that the functional differences are related to rather subtle
alterations in the structure and topology of the protein.
Materials and Methods
Materials
Synthetic peptides PLB1-23WT and PLB1-22R14D, comprising
the first 23 (WT) or 22 (R14D) cytoplasmic residues of PLB and N-
terminally acetylated were supplied by Peptide Protein Research
(PPR Ltd) (Fareham). Full-length synthetic PLBR14D was
purchased from Activotec Ltd (Cambridge). PLB antibodies A1
and PS16 were purchased from Badrilla, and positive reactions
visualised with the WesternBreeze chromogenic immunodetection
kit from Invitrogen. Deuterated phospholipids were purchased
from Avanti-Polar Lipids Inc, amylose resin from New England
Biolabs (NEB), and all other chemicals obtained from Sigma.
Microscope cover glass slides (8 mm622 mm; thickness No. 0
(0.08 to 0.12 mm), used for preparation of oriented protein/lipid
bilayers were purchased from Paul Marienfeld GmbH & Co. KG
(Germany). SERCA1a Ca2+-ATPase was prepared from fast-
twitch rabbit skeletal muscle according to a method adapted from
East and Lee [24]. For assay purposes, purified SERCA1a
membranes were reconstituted in unsaturated L-a-dioleoylpho-
sphatidylcholine (DOPC) membranes alone or co-reconstituted
with full-length PLB.
SDS-PAGE
Analysis of the oligomeric state of PLB was carried out by SDS
PAGE using the Bolt system (Life Technologies). Samples were
prepared as per kit protocol and run on pre-cast 4–12% gradient
Bolt Bis-Tris Plus gels using the MES SDS running buffer.
Expression of PLBWT and PLBR14D
The PLBR14D expression construct was generated from the
human PLBWT DNA sequence, using site-directed ligase-inde-
pendent mutagenesis (SLIM) [25]. Full length (non-acetylated)
PLBWT and the R14D mutant were expressed and purified using
an adaptation of the procedure described by Buck et al. [26]. Both
proteins were expressed in E. coli C41(DE3) as a fusion construct
with maltose binding protein (MBP) using the pMAL c2X vector
(New England Biolabs Inc.) containing the required PLB gene
sequence preceded by an engineered TEV cleavage site [27,28].
After purification on an amylose affinity column and cleavage with
TEV protease [26], PLB was precipitated and isolated from MBP
using a chloroform/methanol extraction procedure [29]. Briefly,
the precipitate, containing PLB, was collected by centrifugation
and dried. The sample was then re-suspended in 50/50
chloroform: acidified methanol (containing 1% acetic acid final
concentration), and stirred at room temperature for two days. The
sample was then filtered through a sinter-glass funnel under
vacuum and the solution, containing solubilised PLB dried under
N2 and high vacuum. Protein purity and identity was confirmed by
MALDI-MS.
Co-reconstitution of PLB with SERCA
PLB variants were reconstituted with SERCA in DOPC
membranes at a lipid/PLB/SERCA ratio of 160:10:1 using an
adaptation of methods described previously [30–32]. Reconstitu-
tion was carried out with SERCA1a, the abundant fast-twitch
skeletal muscle form of the enzyme, which is well established as a
model for SERCA2a function and its inhibition of PLB [33] and is
widely used as a proxy for the cardiac enzyme in structural and
biophysical characterizations. Briefly, DOPC or DOPC and PLB
were dissolved in 50/50 chloroform/methanol and then dried to a
film under a stream of N2 before leaving under high vacuum
overnight. For samples containing PLB only, the dry films were
resuspended in 10 mM phosphate buffer, pH 7.4. For co-
reconstitutions with SERCA, the dry films were dissolved in OG
buffer (10 mM Tris, 0.25 M sucrose 6 mg/ml octyl glucoside
(OG); pH 7.5), prior to addition of SERCA membranes. Samples
were allowed to stir at room temperature for 15 minutes and then
at 4uC for 45 minutes. This was followed by 3 additions of 25 mg
wet biobeads/hour with stirring, for a total of 3 hours.
Membranes were removed from the biobeads, subjected to two
freeze-thaw cycles and frozen at 220uC until ready for assay.
SERCA activity measurements
ATPase activities of SERCA reconstituted alone, with PLBWT,
with PLBR14D or with 1:1 PLBWT: PLBR14D were measured in
a final volume of 200 ml, using 5–10 mg SERCA1a reconstituted as
described above. CaCl2 was added to the required free calcium
concentration. Activity measurements were determined either by a
rapid quench method, or by real time monitoring. For the quench
method, samples were initially prepared in a total volume of
120 ml of reaction buffer (30 mM Tris, pH 8) to which 80 ml of
assay medium (4 mM ATP, 4 mM MgCl2, 0.5 mM EGTA,
30 mM imidazole, pH 7.5) was added. The samples were
incubated for 10 minutes at 37uC and the specific Ca2+-ATPase
activity was quantified as the amount of inorganic phosphate (Pi),
liberated upon hydrolysis of ATP as measured by formation of a
phospho-molybdate complex under acidic conditions [34]. Real
time enzyme activity was determined on a Molecular Devices
FlexStation3 plate reader using a standard coupled enzyme assay
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[35]. The measured activities were normalized to the maximum
activity measured over the calcium concentration range and KCa
values were calculated by non-linear least squares fitting of an
equation for cooperative substrate activation (Hill analysis).
Phosphorylation of PLB
Phosphorylation was carried out by an adaptation of a previous
method, using 0.15 mg each of PLB and R14D solubilised in
0.3 ml of phosphorylation buffer (100 mM MOPS, 10 mM KCl,
8 mMMgCl2, 0.9% OG, 50 nM calyculin A; pH 7.1) [36]. 400 U
of protein kinase A catalytic subunit (PKA), were dissolved in
800 ml 6 mg/ml dithiothreitol (DTT) in MilliQ grade water and
left at room temperature for 10 minutes prior to use. 100 U
(200 ml) were added to each sample to be phosphorylated
including a PKA buffer-only control. Addition of 200 ml 6 mg/
ml DTT was made to non-PKA controls. Phosphorylation was
monitored in real time by a coupled enzyme assay [19,37], with
165 ml of the appropriate phosphorylation reaction mixture added
to PLBWT, PLBR14D, 1:1 PLBWT:PLBR14D and buffer only
control in a 96 well plate, together with a 30 ml volume containing
phosphoenolpyruvate (2 mM), NADH (600 mM), pyruvate kinase
(2 U), and lactate dehydrogenase (2 U), in 50 mM imidazole,
100 mM KCl, 8 mM MgCl2, 0.5 mM EGTA; pH 7.5. Phosphor-
ylation was initiated with 5 ml of 100 mM ATP (pH 7), using the
FlexStation 3 plate reader and monitored at A340 over several
hours for the production of ADP, where [ADP] = DA340/
6.22 mM21cm21. Initial rates of phosphorylation were calculated
by linear regression analysis of the A340 values over the first
20 min after initiation of the reaction.
Successful phosphorylation was further determined by antibody
dot blot analysis using anti-PLB antibody A1 and anti-phos-
phoPLB antibody PS16 (Badrilla). Equal volume aliquots of each
protein or the mixture were applied to two PVDF membranes;
these were then processed simultaneously using the same solutions
differing only at the primary Ab step.
Statistical analysis
KCa values and phosphorylation rates are presented as means6
SEM. Multiple group comparisons were performed using one-way
ANOVA with Tukey’s post hoc test (Minitab 17). P,0.05 was
considered significant in all analyses.
Spectroscopic measurements
Far-UV circular dichroism measurements were carried out on a
Jasco J-180 spectropolarimeter. Circular dichroism (CD) spectra
were recorded from 250 to 195 nm using a 0.1 cm cuvette, a scan
rate of 20 nm/min and an average of 4 accumulations per sample.
All peptides were prepared to 100 mM in 10 mM phosphate,
pH 7. Measurements were made using a stepwise titration with
trifluoroethanol (TFE) to generate measurements up to 40% TFE.
Controls were carried out by titrating TFE into buffer minus the
peptides and deducting the values obtained from the experimental
values.
Isothermal titration calorimetry
Heat flow resulting from binding of lipid small unilamellar
vesicle (SUV’s), to NAcPLB23WT or NAcPLB23R14D was
measured using the ultrasensitive iTC200 MicroCalorimeter
(MicroCal LLC, Northampton, MA). Reaction cell volume and
total injection volume were 200 ml and 40 ml respectively.
Experiments were performed at 25uC, at a power reference
setting of 6 mcal/sec with stirring at 800 rpm. Data analysis was
carried out using the Origin v.7 software (MicroCal) and fitted
using the ‘one set of sites’ model. The reaction cell contained a
100 mM solution of peptide in 10 mM Tris; 1 mM EDTA, 30 mM
NaCl; pH 7.4. Lipid SUV’s comprising 10 mM 2:1 L-a-dimyr-
istoylphosphatidylcholine/L-a-phosphattidylglycerol (DMPC/
DOPG) in the same buffer, were prepared using a probe
sonicator and sonicated at 50% duty cycle for 2630 s and
injected via the syringe. Titrations were carried out at intervals
up to 2 minutes in 1 or 2 ml aliquots following an initial 0.5 ml
discard aliquot. Each injection generates a heat of reaction,
determined by integration of the individual peaks from the heat
flow trace.
NMR measurements on oriented membrane samples
Uniformly 15N labelled full-length PLBWT or PLBR14D
prepared recombinantly were reconstituted with 4:1 DOPC/
DOPE (L-a-dioleoylphosphatidylethanolamine) with a total of
50 mg of lipid. Samples were solubilised in up to 2 ml 50/50
chloroform: acidified methanol (1% acetic acid), before transfer-
ring to , 25 glass plates (8622 mm, thickness No. 0 (0.08–
0.12 mm)), in a series 20 ml repeated aliquots, which were allowed
to dry between additions. The plates were then transferred to a
desiccating cabinet for several days and allowed to dry. The
samples were hydrated either by applying a 10 ml aliquot of MilliQ
grade water and transferring to a humidifier at 37uC or in the case
of PLBR14D by omitting the addition of water and transferring
directly to the humidifier. The samples were again left for several
days until fully hydrated before stacking and wrapping in cling film
ready for analysis by solid state NMR. The stacked plates were
inserted into a Bruker double resonance flat coil probehead
equipped with coil of dimensions 96963 mm and 15N NMR
spectra were acquired on a Bruker Avance 400 NMR spectrom-
eter operating at a frequency of 400.13 MHz for protons. Spectra
were obtained with Hartmann-Hahn cross polarization at a
contact time of 1 ms and proton field of 63 kHz, and recycle delay
of 1 s. Each spectrum was the result of accumulating between
300,000 and 400,000 transients, and so the experimental
temperature was reduced to 210uC to avoid sample dehydration
over the lengthy acquisition times. 31P spectra of the lipid
headgroups were obtained under the same conditions before and
after the 15N measurements to confirm the macroscopic alignment
of the membrane sample.
Magic-angle spinning NMR
Chain perdeuterated DMPC membranes containing PLBWT
or PLBR14D (at a lipid:protein molar ratio of 20:1) were
rehydrated in 10 mM phosphate, pH 7 and centrifuged at
13000 rpm in a bench top microfuge. Pellets were transferred to
a 4 mm diameter zirconia magic angle spinning (MAS) rotor.
NMR measurements were carried out on a Bruker Avance 400
spectrometer equipped with a 4 mm triple resonance magic-angle
spinning (MAS) probehead. The refocused INEPT (rINEPT)
experiment was used to obtain two-dimensional 1H-13C spectra at
4uC and a MAS frequency of 8 kHz. Spectra were acquired using
the States-TPPI method to obtain phase-sensitive quadrature
detection in the indirect dimension and 64 increments were
collected in t1.
Results
Effect of the R14D mutation on the PLB oligomeric state
Immunoblotting analysis of N-flag tagged PLB suggested that
the R14D mutation may partially destabilise the pentamer form of
the peptide generating different sized oligomers [17]. To
investigate the oligomeric state of untagged mutant and wild-type
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PLB proteins in SDS detergent (Figure 1), samples of recombinant
PLBWT and PLBR14D both in isolation and co-reconstituted
with SERCA under the same conditions as those used for
functional assays, were solubilised in lithium dodecyl sulphate
(LDS) sample buffer and analysed by SDS-PAGE. Both recom-
binant variants in isolation show a high proportion of pentameric
protein (lanes 2 and 5). In the presence of SERCA, PLBR14D
(lane 6), is still predominantly pentameric with a small amount of
monomeric/dimeric protein present, and PLBWT (lane 3),
demonstrates a greater shift towards the dimeric and monomeric
forms. Hence in our hands, untagged PLBR14D retains a high
propensity to assemble into pentamers in a lipid-like environment.
However, these data do not rule out the possibility that subtle
differences in the pentamer-monomer distributions of PLBWT
and PLBR14D could occur in more native-like membrane
environments, which might alter their relative effects on SERCA
function.
Effect of the R14D mutation on PLB function
Studies were carried out to determine the regulatory effect of
recombinant PLBWT, PLBR14D and an equimolar mixture of the
two (i.e., analogous to the heterozygous state) on SERCA when
incorporated with the enzyme in DOPC membranes. Calcium-
dependent ATPase activity measurements (Figure 2 and Table 1)
confirm that PLBWT significantly lowers the affinity of SERCA
for calcium relative to the control (SERCA only) sample.
PLBR14D also lowers the calcium affinity of SERCA relative to
the control, but is significantly less inhibitory than PLBWT under
the same conditions (Table 1). This trend agrees with Ceholski et
al. [23], who also reported a slightly reduced inhibitory effect of
PLBR14D alone compared to PLBWT. In an equimolar mixture
of PLBWT and PLBR14D the inhibitory effect is not significantly
different from that of the mutant form alone (Table 1), in
agreement with the findings of Ceholski et al [38]. As argued by
these authors, the lack of the superinhibitory effect reported by
Haghighi et al. [17] may be a result of separating the proteins from
other cellular components into proteoliposomes.
PLBR14D was next tested for its ability to undergo PKA-
catalysed phosphorylation when incorporated alone into DOPC
membranes and whether it interferes with phosphorylation of
PLBWT in a 1:1 mixture. The reaction was carried out with
protein at a concentration of ,40 mM and the presence of
phosphorylated protein was confirmed by antibody (Ab) dot blot
(Figure 3a). Ab A1 reacts with all forms of PLB, generating a
positive control for the presence of PLBWT and PLBR14D,
whereas Ab PS16 reacts only with phosphorylated forms of PLB.
Figure 3a indicates that PLBWT and PLBR14D stain equally
strongly with A1, but PLBR14D stains substantially more weakly
with PS16 than does PLBWT, suggesting that the R14 deletion
impairs phosphorylation. A negative control, comprising the first
26 residues of sarcolipin (SLN1-26), which is highly homologous to
PLB, generated no reaction with either PLB Ab (data not shown).
It should be noted that the R14D mutation occurs within the
epitope region for A1 (L7 – S16), and PS16 (R9 – S16 (PO4)), and
could therefore negatively impact on their ability to react to the
mutant form of PLB. The PS16 Ab is more likely to be affected
since this is much more specific than A1, a more promiscuous Ab
Figure 1. Analysis of the oligomeric distribution of wild-type
and mutant PLB by SDS-PAGE: Comparison of recombinant PLBWT
and PLBR14D in isolation and reconstituted with SERCA (Rec WT and
Rec R14 D) at an approximate molar ratio of 20:1 PLB/enzyme. SERCA is
also shown alone (right hand lane). All samples were prepared
following the standard protocol and solutions provided with the Bolt
system (Life Technologies), and then stained with standard Coomassie
Brilliant Blue R250. The SeeBlue Plus2 Pre-Stained Standards were also
supplied with the Bolt system; the apparent molecular weights shown
on the gel are those expected when run on a NuPAGE Novex 4–12%
Bis-Tris Gel with MES. Protein migration patterns are dependent on the
buffer system used; in a more typical Tris/Glycine system, the migration
pattern of the same markers would differ, with apparent molecular
weights as follows: 4, 6, 16, 22, 36, 50, 64, 98, 148 and 250.
doi:10.1371/journal.pone.0106746.g001
Figure 2. ATPase activity of SERCA: Normalised ATP hydrolysis by
SERCA alone (open circles), or reconstituted with full-length recombi-
nant PLBWT (squares), PLBR14D (open triangles), or an equimolar mix of
mutant and WT (inverted triangles), with activity measured as a function
of calcium concentration (n = 6). Samples were reconstituted with the
enzyme in DOPC membranes at a lipid/protein/enzyme ratio of 160:2:1
and activities were determined in real time using the coupled enzyme
assay.
doi:10.1371/journal.pone.0106746.g002
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capable of reacting with multiple forms of PLB. This may in part
account for the minimal reaction of PS16 with PKA treated
PLBR14D. Qualitative inspection of the PS16 blot for the mixed
PLBWT and PLBR14D sample in Figure 3a implies that
PLBR14D does not substantially impair the ability of PKA to
phosphorylate PLBWT.
While Ab dot blot analysis is a useful technique for detecting
and confirming the presence of phosphorylated protein, it tells us
nothing about the rate or efficiency of phosphorylation. A second
measure of phosphorylation was used, therefore, in which the
production of ADP during the PKA-catalysed reaction is linked to
oxidation of NADH using the coupled enzyme assay, and
monitored by observing the absorbance at A340 (Figure 3b). This
allows PKA activity to be monitored in real-time (Figure 3b) [37],
and is a technique used in previous studies with the PLBR9C
mutant [19]. Measurements were carried out for both PKA
treated samples and untreated controls in addition to a PKA
control in the absence of PLB protein. The rate of NADH
oxidation is determined by the concentration of ADP present in
the samples, which in turn is determined by the level of successful
phosphorylation. Figure 3b clearly shows that phosphorylation of
PLBR14D alone occurs at a significantly slower rate (1662 mM
h21) than the phosphorylation of PLBWT (3863 mM h21, p,
0.05), as reflected in the dot blotting data representing the end-
point of the phosphorylation reaction. In an equimolar
PLBR14D/PLBWT mixture the overall rate of phosphorylation
of PLBWT (3064 mM h21) is not significantly different from
PLBWT alone (p.0.05), also in agreement with the dot blotting
data. Together these results indicate that the R14D mutation
impedes PKA-dependent phosphorylation of PLBWT, as reported
in earlier work [23].
Structure and dynamics of the PLBR14D cytoplasmic
domain
We next investigated whether the functional characteristics of
the R14D mutation, and its resistance to phosphorylation in the
cytoplasmic domain, originate from structural modifications to the
protein. Peptides representing the cytoplasmic domains of
PLBWT and PLBR14D (PLB1-23WT and PLB1-22R14D) were
analysed for differences in overall secondary structure using CD
spectroscopy and titrating the peptides with TFE to stabilise any
intrinsic helical structure. The spectra are consistent with a shift
from an unstructured state in 0% TFE (Figure 4a), to a more
typically a-helical structure at 40% TFE (Figure 4b). Further
titration of TFE into both peptide solutions did not result in
further changes to the spectrum. By monitoring the decrease in
molar ellipticity at 222 nm (after adjusting for sample volume), the
spectra indicate that the WT sequence has a greater propensity to
form an a-helix than the R14D mutant (Figure 4c).
We next turned attention to the effect of the R14 deletion on the
membrane topology of PLB, and specifically the relative orienta-
tions of the cytoplasmic and transmembrane domains. We
prepared uniaxially aligned samples of uniformly 15N labelled
PLBR14D and PLBWT in DOPC/DOPE membranes and
obtained 15N cross-polarization NMR spectra of the samples
aligned in the magnet with the membrane normal approximately
parallel with the applied field (as confirmed by the narrow 31P
NMR spectra for the lipid headgroups; data not shown). Under
these conditions the 15N spectra are consistent with the proteins
having a unique orientation in the magnetic field, and despite the
Table 1. Activity of SERCA when reconstituted with PLB variants.
kCa DpkCa
Control (SERCA only) 0.50 (60.30)a -
With PLBWT 2.75 (60.42)b* 20.74
With PLBR14D 0.89 (60.10)c 20.25
With 1:1 PLBWT:PLBR14D 0.70 (60.15)c 20.15
Values are means 6 SEM. Ca2+-ATPase activities of reconstituted samples (n = 6) were measured over calcium concentrations from pCa 7.5 to pCa 5.0. Kca is the calcium
concentration (in mM) required for half-maximal activity, determined by Hill analysis. pkCa is the negative logarithm of kCa. Means that do not share a letter (superscript a,
b or c) are significantly different (P,0.05). *indicates p,0.01 vs control.
doi:10.1371/journal.pone.0106746.t001
Figure 3. PKA-catalysed phosphorylation of PLBWT and
PLBR14D: Relative ability of PKA to phosphorylate PLBWT, PLBR14D
and an equimolar mix of PLB conformers was measured by a) dot blot
analysis using PLB Ab A1 to detect both phosphorylated and
unphosphorylated protein and Ab PS16 to detect phosphorylated
forms of PLB only; b) real time measurement of ADP production
resulting from successful PKA phosphorylation. Data (n = 3) were
measured in triplicate in a single 96 well plate experiment and for
clarity only the mean values are shown.
doi:10.1371/journal.pone.0106746.g003
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low signal to noise some differences between the spectra of wild-
type and mutant proteins could be discerned. The spectrum of
PLBWT exhibits a line shape with enhanced intensity around 60–
120 ppm and 200 ppm and very little signal from 120–200 ppm.
This line shape is consistent with helical domains oriented
approximately perpendicular and parallel to the bilayer normal,
respectively. A theoretical 15N spectrum was simulated from the
atomic coordinates for PLBWT pentamers in the ‘‘pin-wheel’’
structure of the T-state (2KYV: Figure 5a) with the cytoplasmic
domain approximately parallel with the membrane surface (12).
The theoretical 15N spectrum is qualitatively rather similar to the
experimental spectrum, suggesting that under these conditions
(and in the same membrane composition as for the published
structure) PLBWT adopts a structure reminiscent of the T-state.
The spectrum of PLBR14D covers the 100–200 ppm range with a
maximum around 200 ppm, suggesting that there is overall much
more orientational disorder in the mutant (Figure 5b).
These results suggest that the R14 deletion tends to alter the
average orientation of the cytoplasmic domain, such that it moves
away from the membrane surface. PLBWT has been found to
populate two major topological states in equilibrium, one in which
the amphipathic cytoplasmic domain is structurally ordered and
approximately parallel to the membrane surface (‘‘T-state’’) and
the other in which the cytoplasmic domain is dynamically
disordered and dissociated from the membrane surface (‘‘R-state’’)
[14]. Here, a 13C-detected refocused INEPT magic-angle spinning
NMR experiment was carried out to detect differences in the
mobility of the cytoplasmic regions of uniformly 13C-labelled
PLBWT and PLBR14D reconstituted into chain-perdeuterated
DMPC membranes. The refocused INEPT experiment has
previously been shown to detect the cytoplasmic region in the
R-state because the mobility of this region gives rise to long
transverse relaxation times [39]. Hence we reasoned that
differences in the number and intensity of the observed resonances
in the refocused INEPT spectra of the two PLB variants, all other
considerations being equal, would signify differences in the
mobility of the cytoplasmic domains and in the position of the
equilibrium between the R- and T-states. The spectra of PLBWT
and PLBR14D in DMPC membranes at 30uC are shown in
Figure 6. The hydrocarbon chains of the lipid would normally give
rise to a strong background signal and so DMPC was used here
because the perdeuterated lipid is commercially available.
Although it was not possible to assign the spectra from the
measurements performed, it is clear that the spectrum of
PLBR14D (Figure 6a) exhibits considerably more resonances than
the spectrum for PLBWT (Figure 6b) owing to the longer 1H and
13C transverse relaxation times for the mutant. Hence the
spectrum of PLBR14D suggests that the dynamic equilibrium is
shifted toward a more disordered state in comparison to the more
structurally ordered cytoplasmic domain of PLBWT.
The ordered T-state of PLB may depend in part on the
amphipathic cytoplasmic helix being stabilised by electrostatic
interactions with the membrane surface, i.e., the phospholipid
headgroups. If PLBR14D is predisposed toward the more
disordered state as suggested by the NMR measurements, this
may arise from a weakening of the stabilising membrane
interactions resulting from the loss of the cationic arginine residue.
Isothermal titration calorimetry was used therefore to determine
the relative affinities of the PLBWT and PLBR14D cytoplasmic
domains (represented by PLB1-23WT and PLB1-22R14D) for
phospholipid membrane surfaces. Previous work demonstrated
that SUV’s of 2:1 DMPC/DOPG are a useful model system to
compare the membrane affinities of amphipathic peptides, giving
measureable enthalpic changes for PLB1-23WT ([40] and Fig-
ure 7a). Here, titrations of DMPC/DOPG SUV’s into a solution
of PLB23R14D do not give rise to measureable enthalpic changes
(Figure 7b), indicating that for this combination of phospholipids
the membrane interactions of PLB23R14D are substantially
weaker than for PLBWT.
Figure 4. Secondary structure comparison of the cytoplasmic
domains (residues 1-23) of PLBWT and PLBR14D by circular
dichroism: Spectra are shown for peptides dissolved in a) water and b)
60% water:40% TFE. c) Molar elipticity at 222 nm monitored during TFE
titration from 0% to 40% to determine the peptides relative ability to
form secondary structure. A decrease in molar elipticity at 222 nm is
diagnostic of a shift towards an a-helical structure.
doi:10.1371/journal.pone.0106746.g004
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Discussion
We have used a variety of techniques to investigate the
functional and conformational properties of PLBWT and the
mutant PLBR14D lacking R14 in the cytoplasmic domain. It is
generally accepted that PLBWT reduces the Km of SERCA for
calcium, but it has been variably shown to decrease or increase
Vmax or to have no effect [32,35,41–44]. Here we find that
PLBR14D is a slight loss of function mutant that is capable of
interacting with SERCA and lowering its affinity for calcium, but
to a lesser degree than PLBWT alone (Figure 2). When the mutant
was reconstituted together with PLBWT, the functional effects are
typical of those seen for PLBR14D alone. Previously, in work using
HEK-293 cells transfected with N-Flag tagged PLB constructs, the
R14D mutation had been described as super-inhibitory, but only
when it occurs in the WT/mutant heterozygous state [17].
Consistent with our work they also found homozygous PLBR14D
to be a slight loss of function mutation. Variation in results could
potentially be explained by differences in both assay method and
the PLB constructs used. Our results however agree with more
recent work that examined a series of targeted mutations in the
PLB cytoplasmic domain, and suggested that correct hydrophobic
balance in this region is critical for correct regulation of SERCA
[38]. It also highlights the importance of the role played by the
cytoplasmic domain in the functional regulation of SERCA. The
dominant effect of PLBR14D over PLBWT suggests that the
mutant form successfully competes with the wild-type protein for
association with the enzyme. This is also consistent with work seen
elsewhere in which loss of function PLB mutants have been shown
to compete with PLBWT for SERCA association in both
reconstituted systems [45] and living cells [46].
The diminished capacity of PLBR14D to inhibit SERCA may
arise from changes to the oligomeric status of the PLB mutant. It is
widely recognised that PLB is more inhibitory as a monomer
[8,47,48], than it is in its pentameric state and thus the reduced
efficiency of SERCA inhibition by PLBR14D might reflect
alterations in the monomer-pentamer equilibrium. It has been
suggested that, in comparison to WT PLB, PLBR14D tends to be
more monomeric [17] which was proposed to account for the
super-inhibitory effect of the mutant observed in that study. Here,
SDS-PAGE analysis indicates that while recombinant PLBWT
and PLBR14D in isolation are both predominantly pentameric in
detergent, when reconstituted with SERCA, PLBWT more readily
dissociates in to the monomeric form than PLBR14D. In the
absence of precise quantitative information on the populations of
monomer and pentamer in lipid membranes, it cannot be ruled
Figure 5. NMR analysis of the domain orientations of PLBWT and PLBR14D in aligned lipid membranes: 15N NMR measurements were
carried out on aligned membranes of 4:1 DOPC/DOPE containing uniformly 15N labelled recombinant PLBWT or PLBR14D. a) ‘‘Pinwheel’’ structure of
PLB in the T-state taken from the PDB coordinates (2KYV) with a simulated spectrum calculated from 2KYV. Only main-chain 15N resonances were
included in the simulations of the spectra because of uncertainties in the orientation of the side-chains. b) Experimental spectrum for PLBWT. c)
Experimental spectrum for PLBR14D.
doi:10.1371/journal.pone.0106746.g005
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out that small differences in the monomer-pentamer ratios of
PLBR14D and PLBWT give rise to the functional differences
observed here.
The loss of function of PLBR14D may arise from the preference
of the cytoplasmic domain to adopt a structurally disordered,
membrane-disordered state akin to the R-state observed for the
wild-type protein. The PLBWT cytoplasmic domain can undergo
a shift from a folded, membrane-associated T-state to an unfolded,
excited, membrane free R-state [10,12,14,40]. CD analysis
(Figure 4) indicates that the cytoplasmic domain of PLBR14D in
aqueous solution has a lower a-helical content than the
corresponding region of the wild-type protein. Moreover, NMR
measurements (Figures 5 and 6) are broadly consistent with the
cytoplasmic domain of PLBR14D being more dynamically
disordered and oriented further away from the membrane surface
compared to PLBWT. Reduced interactions with the membrane
surface are supported by ITC measurements (Figure 7) which
indicate that PLB1-23R14D interacts more weakly with membranes
than does PLB1-23WT. The effects of the membrane environment
on PLB structure and function are well established, with
membranes representative of SR favouring a non-extended PLB
conformation with an T-type structure [49]. In dodecylpho-
sphocholine (DPC), the T (folded, membrane associated), and T’-
states (partially folded, membrane associated), are observed
whereas in DMPC the R-state (unfolded, membrane dissociated),
predominates. Lipid head-group charge, bilayer curvature/thick-
ness all influence the conformational equilibrium and the extent of
PLB aggregation [14]. Molecular dynamics simulations of the PLB
structure in DOPC bilayers [10,12] revealed that residue R13
residues is solvent exposed and accessible to PLB binding partners,
while R14 appears to dip in to the membrane surface contacting
lipid bilayer head-groups where it forms hydrogen bonds with the
oxygen atoms of the DOPC glycerol moiety. Hence deletion of
R14 may weaken this interaction and destabilise the membrane-
associated state of the mutant.
The phosphorylation measurements reported here (Figure 3)
agree with earlier results [22,23] and indicate that the R14
deletion impairs the PKA-dependent phosphorylation of PLB,
Figure 6. Solid-state NMR spectra of PLBWT and PLBR14D in
unoriented membranes: 1H-13C rINEPT solid-state NMR spectra are
shown for uniformly 13C-labelled PLBR14D (a) and PLBWT (b) prepared
in 4:1 DOPC/DOPE membranes. Red asterisks indicate the positions of
lipid resonances.
doi:10.1371/journal.pone.0106746.g006
Figure 7. Analysis of PLB interactions with lipid SUV’s using isothermal titration calorimetry: Cytoplasmic peptides PLB23R14D (a), and
PLB23 (b), were titrated with 2:1 DMPC/DOPG lipid SUV’s to determine their relative ability to associate with lipid membrane surfaces. Titration curves
of integrated enthalpy versus mole ratio of reactants are shown with solid lines representing the best fitting curves.
doi:10.1371/journal.pone.0106746.g007
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either by modifying the enzyme recognition site, perturbing the
protein conformation, or both. The lower inhibitory function of
PLBR14D may thus be compensated by the resistance of the
mutant to phosphorylation, which in the cellular environment may
give rise to constitutive inhibition of SERCA and the disruption of
calcium transients. Such effects in the long term may explain the
occurrence of DCM in patients that possess the R14D mutation.
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